



MISSISSIPPI DIVISION OF
MEDICAID

MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting
Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

May 9, 2017
10:00am to 5:00pm

MINUTES

Committee Members Present:

Jeffrey A. Ali, M.D., M.Sc.
Logan Davis, Pharm.D., MBA
Deborah Minor, Pharm.D.
Jason Parham, M.D.
D. Stanley Hartness, M.D.
Wilma Wilbanks, R.Ph.
Ryan Harper, Pharm.D.
Geri Lee Weiland, M.D.
Steven V. Dancer, R.Ph.
John Cook, M.D.

Committee Members Not Present:

Anne A. Norwood, CFNP, Ph.D.
Maretta Walley, R.Ph., J.D.

Division of Medicaid Staff Present:

Terri Kirby, B.S.Pharm., R.Ph., Pharmacy Director
Cindy Noble, Pharm.D., MPH, Pharmacist III
Gail C. McCorkle, BS Pharm., R.Ph., Pharmacist III
Dorothy Young, Ph.D., Deputy Director of Health
Services
Chris A. Yount, MA, PMP, Staff Officer III

Contract Staff/CHC Staff Present:

Chad Bissell, Pharm.D., MBA
Laureen Biczak, D.O.
Paige Clayton, Pharm.D.
Shannon Hardwick, R.Ph.

Other Contract Staff Present:

Karen Powell, Pharm.D., Conduent
Lew Ann Snow, R.N., Conduent
Ben Banahan, Ph.D., UM School of Pharmacy
Eric Pittman, Pharm.D., UM School of
Pharmacy

I. Call to Order

Ms. Wilma Wilbanks, Chairperson, called the meeting to order at 10:00 a.m.

II. Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Change Healthcare, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby recognized DOM contractors in the audience, including Dr. Karen Powell and Lew Ann Snow from Conduent, and Drs. Ben Banahan and Eric Pittman from the University of the Mississippi School of Pharmacy's MS-DUR Program and Change Healthcare(CHC) contractors, Dr. Paige Clayton and Shannon Hardwick.

III. Administrative Matters

Ms. Kirby reminded guests that if they did not sign the sign-in sheet prior to entering the room, to please do so. She stated that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 5 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and pagers, laptop usage, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no later than May 30, 2017. Decisions will be announced no later than June 1, 2017 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

IV. Division of Medicaid Update

Ms. Kirby provided an update on the upcoming changes to the pharmacy reimbursement methodology, including the use of National Average Drug Acquisition Cost (NADAC).

V. Approval of February 28, 2017 Meeting Minutes

Ms. Wilbanks asked for additions or corrections to the minutes from the February 28, 2017 meeting. There were no further additions or corrections. The minutes stand approved.

VI. PDL Compliance/Generic Percent Report Updates

Dr. Biczak provided an explanation of the PDL Compliance and Generic Percent reports.

- A.** Dr. Biczak reviewed the PDL Compliance Report; overall compliance for Q1 2017 was 97.7%.
- B.** Dr. Biczak reviewed the Generic Percent Report; overall generic utilization for Q1 2017 was 86.8%.

VII. Drug Class Announcements

Dr. Bissell reviewed the meeting format.

VIII. Public Comments

Melanie Brenner from Opko spoke in favor of Rayaldee.

Lee Ann Griffin from Pfizer spoke in favor of Eucrisa.

Maria Sciame from Shire spoke in favor of Cuvitru.

IX. New Therapeutic Class Reviews

A. Hepatitis B Treatments

CHC recommended that the following list be approved. A clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Dancer seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
entecavir EPIVIR HBV SOLUTION (lamivudine) lamivudine HBV VIREAD (tenofovir disoproxil fumarate)	adefovir dipivoxil BARACLUDE (entecavir) EPIVIR HBV TABLET (lamivudine) HEPSERA (adefovir dipivoxil) TYZEKA (telbivudine) VEMLIDY (tenofovir alafenamide fumarate)

B. Hypoglycemics, Biguanides

CHC recommended that the following list be approved. Dr. Minor moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
metformin HCL tablet metformin HCL ER 24HR tablet	FORTAMET ER GLUCOPHAGE GLUCOPHAGE XR GLUMETZA (metformin) metformin 24HR (generic Fortamet) metformin 24 HR(generic Glumetza) RIOMET SOLUTION

X. New Drug/New Generic Reviews

A. Rubraca

CHC recommended that Rubraca be made Non-Preferred in the Antineoplastics – Selected Systemic Enzyme Inhibitors category. Dr. Weiland moved to accept the recommendation. Dr. Davis seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
AFINITOR (everolimus) BOSULIF (bosutinib) CAPRELSA (vandetanib) COMETRIQ (cabozantinib) COTELLIC (cobimetinib) GILOTRIF (afatanib)	ALECENSA (alectinib) CABOMETYX (cabozantinib s-malate) FARYDAK (panobinostat) GLEOSTINE (Iomustine) IBRANCE (palbociclib) ^{SmartPA}

PREFERRED AGENTS	NON-PREFERRED AGENTS
GLEEVEC (imatinib mesylate)	KISQALI (ribociclib) ^{NR}
ICLUSIG (ponatinib)	LENVIMA (lenvatinib)
IMBRUVICA (ibrutinib)	LYNPARZA (olaparib)
INLYTA (axitinib)	RUBRACA (rucaparib)
IRESSA (gefitinib)	TAGRISSE (osimertinib)
JAKAFI (ruxolitinib)	
MEKINIST (trametinib dimethyl sulfoxide)	
NEXAVAR (sorafenib)	
SPRYCEL (dasatinib)	
STIVARGA (regorafenib)	
SUTENT (sunitinib)	
TAFINLAR (dabrafenib)	
TARCEVA (erlotinib)	
TASIGNA (nilotinib)	
TYKERB (lapatinib ditosylate)	
vandetanib	
VOTRIENT (pazopanib)	
XALKORI (crizotinib)	
ZELBORAF (vemurafenib)	
ZYDELIG (idelalisib)	
ZYKADIA (ceritinib)	

B. Eucrisa

CHC recommended that Eucrisa be made Non-Preferred in the Atopic Dermatitis category. Dr. Minor moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ELIDEL (pimecrolimus)	EUCRISA (crisaborole)
	PROTOPIC (tacrolimus)
	tacrolimus

C. Cuvitru

CHC recommended that Cuvitru be made Non-Preferred in the Immune Globulins category. Dr. Weiland moved to accept the recommendation. Dr. Cook seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
CARIMUNE NF	BIVIGAM
FLEBOGAMMA DIF	CUVITRU
GAMASTAN SD	GAMMAGARD SD
GAMMAGARD	GAMMAPLEX
GAMMAKED	PRIVIGEN
GAMUNEX-C	
HIZENTRA	
HYQVIA	
OCTAGAM	

D. Adlyxin & Soliqua

CHC recommended that Adlyxin and Soliqua be made Non-Preferred in the Hypoglycemics, Incretin Mimetics/Enhancers category. Dr. Minor moved to accept the recommendation. Dr.

Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BYDUREON (exenatide) VICTOZA (liraglutide)	ADLYXIN (lixisenatide) BYETTA (exenatide) SOLIQUA (insulin glargine/lixisenatide) SYMLIN (pramlintide) TANZEUM (albiglutide) TRULICITY (dulaglutide)

E. Basaglar

CHC recommended that Basaglar be made Non-Preferred in the Hypoglycemics, Insulins and Related Agents category. Dr. Weiland moved to accept the recommendation. Dr. Cook seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
HUMALOG VIAL (insulin lispro) HUMALOG MIX VIAL (insulin lispro/ lispro protamine) HUMULIN VIAL (insulin) LANTUS SOLOSTAR & VIAL (insulin glargine) LEVEMIR FLEXPEN & VIAL (insulin detemir) NOVOLOG FLEXPEN & VIAL (insulin aspart) NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ aspart protamine)	AFREZZA (insulin) APIDRA (insulin glulisine) BASAGLAR (insulin glargine) HUMALOG KWIKPEN (insulin lispro) HUMALOG MIX KWIKPEN (insulin lispro/ lispro protamine) HUMULIN KWIKPEN (insulin) NOVOLIN FLEXPEN (insulin) NOVOLIN VIAL (insulin) TOUJEO (insulin glargine) TRESIBA (insulin degludec)

F. Rayaldee

CHC recommended that Rayaldee be made Non-Preferred in the Parathyroid Agents category. Dr. Harper moved to accept the recommendation. Dr. Parham seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
calcitriol ergocalciferol paricalcitol ZEMPLAR (paricalcitol)	doxercalciferol DRISDOL (ergocalciferol) HECTOROL (doxercalciferol) NATPARA (parathyroid hormone) RAYALDEE (calcifediol) ROCALTROL (calcitriol) SENSIPAR (cinacalcet)

XI. Other Business

XII. Next Meeting Date

The next meeting of the Pharmacy & Therapeutics Committee will be held on August 8, 2017 at 10:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi.

XIII. Adjournment

The meeting adjourned at 11:35 a.m.